Geninn Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 16-11-2024
- Paid Up Capital ₹ 1.00 M
as on 16-11-2024
- Company Age 5 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Revenue 22.75%
(FY 2023)
- Profit 16.67%
(FY 2023)
- Ebitda -9.21%
(FY 2023)
- Net Worth 10.24%
(FY 2023)
- Total Assets 0.01%
(FY 2023)
About Geninn Life Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Venugopal Ghanta and Srinivas Vasireddy serve as directors at the Company.
- CIN/LLPIN
U24299TG2019PTC136520
- Company No.
136520
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
31 Oct 2019
- Date of AGM
22 Jul 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Medak, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Geninn Life Sciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Venugopal Ghanta  | Director | 05-Jun-2021 | Current |
| Srinivas Vasireddy | Director | 22-Oct-2022 | Current |
Financial Performance and Corporate Structure Insights of Geninn Life Sciences.
Geninn Life Sciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 22.75% increase. The company also saw a substantial improvement in profitability, with a 16.67% increase in profit. The company's net worth Soared by an impressive increase of 10.24%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Geninn Life Sciences?
In 2023, Geninn Life Sciences had a promoter holding of 40.90% and a public holding of 59.10%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Vindhya Organics Private LimitedActive 36 years 10 monthsVenugopal Ghanta and Srinivas Vasireddy are mutual person
- Vindhya Pharma (India) Private LimitedActive 18 years 4 months
Srinivas Vasireddy is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Geninn Life Sciences?
Unlock and access historical data on people associated with Geninn Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Geninn Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Geninn Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
